Skip To Content

More options are needed
for myelodysplastic syndromes (MDS)

A clinical research study is now enrolling for MDS and MDS-related anemia.

You may be invited to participate in the ELRiSE MDS Study if you:

  • Are 18 years old or older
  • Have been diagnosed with very low-, low-, or intermediate-risk MDS
  • Have anemia that requires blood transfusions
  • Have not yet received treatment for MDS

If you are interested in participating, ask your doctor if this study may be right for you. The study doctor or staff will review additional study criteria with you.

Participants will receive all study-related care at no cost, and they may be reimbursed for travel and study-related expenses, where permitted by local laws and regulations.

About the
ELRiSE MDS Study

The ELRiSE MDS Study is evaluating an investigational study drug compared to a standard-of-care drug to learn if it can safely and effectively reduce the need for blood transfusions in people with MDS and MDS-related anemia. An investigational study drug is a drug that has not been approved by the FDA for sale or prescription and is currently being investigated in a clinical research study.

What to expect:

  • A screening period to determine eligibility
  • Regular study visits with a dedicated study team
  • An injection under the skin given weekly for the standard-of-care drug or monthly for the investigational study drug
  • Ongoing monitoring throughout the study

During the study, you will have an equal chance of receiving either the investigational study drug or the standard-of-care drug. The standard-of-care drug is recommended by international medical guidelines based on multiple studies in patients with lower-risk MDS that demonstrated improvements in anemia symptoms.1 The investigational study drug is designed with the intent to block proteins in the blood that interfere with your body’s ability to make red blood cells.

Total participation time will depend on each participant’s response to the investigational study drug or standard-of-care drug.

Research shows that some diseases and medicines can affect people in different ways. This can depend on things like age, sex assigned at birth, race, and ethnic background. That’s why clinical studies should include participants who reflect the people living with the disease.

For Healthcare Professionals

  • Phase 3, multicenter, open-label, randomized
  • Evaluating an investigational study drug in participants who are transfusion-dependent and have not yet received front-line treatment for their MDS-related anemia
  • Target enrollment: ~210–300 participants

Please consider patients with:

  • Myelodysplastic syndromes (very low-, low-, or intermediate-risk)
  • Ongoing transfusion requirements
  • Limited available treatment options

  • To evaluate the efficacy of the investigational study drug on red blood cell transfusion dependence for a minimum 12-week period within 24 weeks with concurrent mean hemoglobin increase (greater than or equal to 1.5 g/dL) compared to the standard-of-care drug 

When discussing this clinical research study with your patients, here are some key points to mention: 

  • Participants will receive either the investigational study drug every 4 weeks or the standard-of-care drug once a week. 
  • During the study treatment period, participants will have visits about twice a month as long as the study doctor thinks it is safe and effective for them to continue taking their assigned study drug. 
  • After the study treatment period, participants will receive follow-up phone calls up to 5 years after the date they started study treatment.
  • Study-related care will be provided at no cost.
  • Travel support may be available, where permitted by local laws and regulations.
This clinical research study has the potential to offer a step forward in providing much-needed relief for people with MDS and anemia. We are looking for physicians to review their patients’ charts to see if any of them may be eligible for participation.